Skip to main content

Advertisement

SpringerLink
Log in

Effect duration of the initial course of peroneal electrical Transcutaneous NeuroModulation in patients with overactive bladder

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

The aim of this prospective 12-month follow-up study is to evaluate the persistence of the treatment effect achieved during the initial course of peroneal electrical Transcutaneous NeuroModulation (peroneal eTNM®) in patients with overactive bladder (OAB).

Methods

This study enrolled 21 female patients who participated in two previous clinical studies designed to assess the efficacy and safety of peroneal eTNM®. The patients were left without subsequent OAB treatment and were invited to attend regular follow-up visits every 3 months. The patient’s request for additional treatment was considered an indicator of the withdrawal of the treatment effect of the initial course of peroneal eTNM®. The primary objective was the proportion of patients with persisting treatment effect at follow-up visit 12 months after initial course of peroneal eTNM®. Descriptive statistics are presented using median, correlation analyses were computed using a nonparametric Spearman correlation.

Results

The proportion of patients with persistent therapeutic effect of the initial course of peroneal eTNM® was 76%, 76%, 62% and 48% at 3, 6, 9 and 12 months, respectively. There was a significant correlation between patient reported outcomes and the number of severe urgency episodes with or without urgency incontinence as reported by patients at each follow-up visit (p = 0.0017).

Conclusion

The treatment effect achieved during the initial phase of peroneal eTNM® persists for at least 12 months in 48% of patients. It is likely that the duration of effects is dependent on the length of the initial therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

  1. Huang J, Fan Y, Zhao K et al (2002) Comparative efficacy of neuromodulation technologies for overactive bladder in adults: a network meta-analysis of randomized controlled trials. Neuromodulation S1094–7159(22):00752–00758

    Google Scholar 

  2. Sirls ER, Killinger KA, Boura JA, Peters KM (2018) Percutaneous tibial nerve stimulation in the office setting: real-world experience of over 100 patients. Urology 113:34–39

    Article  PubMed  Google Scholar 

  3. Du C, Berg W, Siegal AR et al (2021) Real-world compliance with percutaneous tibial nerve stimulation maintenance therapy in an American population. Urology 153:119–123

    Article  PubMed  Google Scholar 

  4. Del Río-Gonzalez S, Aragon IM, Castillo E et al (2017) Percutaneous tibial nerve stimulation therapy for overactive bladder syndrome: clinical effectiveness, urodynamic, and durability evaluation. Urology 108:52–58

    Article  PubMed  Google Scholar 

  5. Krhut J, Rejchrt M, Slovak M, Dvorak RV, Peter L, Blok BFM, Zvara P (2023) Prospective, randomized, multicenter trial of peroneal electrical transcutaneous neuromodulation versus solifenacin in treatment of naïve patients with overactive bladder. J Urol 209(4):734–741

    Article  PubMed  Google Scholar 

  6. Krhut J, Rejchrt M, Slovak M, Dvorak RV, Grepl M, Zvara P (2022) Peroneal electrical transcutaneous neuromodulation in the home treatment of the refractory overactive bladder. Int Urogynecol J. https://doi.org/10.1007/s00192-022-05359-3

    Article  PubMed  Google Scholar 

  7. Krhut J, Peter L, Rejchrt M, Slovak M, Skugarevska B, Zvara P (2021) Peroneal electric transcutaneous neuromodulation (eTNM®): a novel method for the treatment of the overactive bladder. J Healthc Eng 2021:4016346

    Article  PubMed  PubMed Central  Google Scholar 

  8. Notte SM, Marshall TS, Lee M et al (2012) Content validity and test-retest reliability of Patient Perception of Intensity of Urgency Scale (PPIUS) for overactive bladder. BMC Urol 12:26

    Article  PubMed  PubMed Central  Google Scholar 

  9. Meadows KA (2011) Patient-reported outcome measures: an overview. Br J Community Nurs 16(3):146–151

    Article  PubMed  Google Scholar 

  10. Agarwal A, Eryuzlu LN, Cartwright R et al (2014) What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. Eur Urol 65:1211–1217

    Article  PubMed  PubMed Central  Google Scholar 

  11. Ghavidel-Sardsahra A, Ghojazadeh M, Rahnama’I MS et al (2022) Efficacy of percutaneous and transcutaneous posterior tibial nerve stimulation on idiopathic overactive bladder and interstitial cystitis/painful bladder syndrome: a systematic review and meta-analysis. Neurourol Urodyn 41:539–551

    Article  PubMed  Google Scholar 

  12. Andersen K, Kobberø H, Pedersen TB, Poulsen MH (2021) Percutaneous tibial nerve stimulation for idiopathic and neurogenic overactive bladder dysfunction: a four-year follow-up single-centre experience. Scand J Urol 55(2):169–176

    Article  CAS  PubMed  Google Scholar 

  13. Finazzi Agrò E, Campagna A, Sciobica F et al (2005) Posterior tibial nerve stimulation: is the once-a-week protocol the best option? Minerva Urol Nefrol 57:119–123

    PubMed  Google Scholar 

  14. Yoong W, Ridout AE, Damodaram M, Dadswell R (2010) Neuromodulative treatment with percutaneous tibial nerve stimulation for intractable detrusor instability: outcomes following a shortened 6-week protocol. BJU Int 106:1673–1676

    Article  PubMed  Google Scholar 

  15. Jung CE, Menefee SA, Diwadkar GB (2020) 8 versus 12 weeks of percutaneous tibial nerve stimulation and response predictors for overactive bladder. Int Urogynecol J 31:905–914

    Article  PubMed  Google Scholar 

  16. Krhut J, Tintěra J, Rejchrt M et al (2023) Brain response induced by peroneal electrical transcutaneous neuromodulation invented for overactive bladder treatment, as detected by functional magnetic resonance imaging. Neuromodulation. https://doi.org/10.1016/j.neurom.2022.11.016

    Article  PubMed  Google Scholar 

  17. Blok BF, Groen J, Bosch JL, Veltman DJ, Lammertsma AA (2006) Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators. BJU Int 98:1238–1243

    Article  PubMed  Google Scholar 

  18. Bianchi D, Iacovelli V, Parisi I et al (2021) Real-life data on long-term follow-up of patients successfully treated with percutaneous tibial nerve stimulation. Minerva Urol Nephrol 73:260–264

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors are grateful to L. Horčička and L. Slobodník for their contribution to the data acquisition.

Funding

The primary trials were funded by STIMVIA™, Ostrava, Czech Republic. The present follow-up study did not receive any funding from public or private sources.

Author information

Author notes

  1. Bertil F. M. Blok and Peter Zvara have equal effort toward authorship.

Authors and Affiliations

  1. Department of Urology, 2nd Faculty of Medicine of Charles University and Motol University Hospital, Prague, Czech Republic

    Michal Rejchrt

  2. Urological Office, Poliklinika RAVAK, Příbram, Czech Republic

    Michal Rejchrt

  3. Department of Urology, University Hospital, Ostrava, Czech Republic

    Jan Krhut

  4. Department of Surgical Studies, Faculty of Medicine, Ostrava University, Ostrava, Czech Republic

    Jan Krhut

  5. Gynuro s.r.o., Ostrava, Czech Republic

    Marcel Gärtner

  6. Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands

    Bertil F. M. Blok

  7. Biomedical Laboratory and Research Unit of Urology, Department of Clinical Research, University of Southern Denmark, Odense, Denmark

    Peter Zvara

  8. Department of Urology, Odense University Hospital, Odense, Denmark

    Peter Zvara

Authors
  1. Michal Rejchrt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan Krhut
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marcel Gärtner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bertil F. M. Blok
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peter Zvara
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MR: contributed to study concept, data acquisition, data analysis, and manuscript revision; JK: contributed to study concept, study design, data acquisition, data analysis, interpretation of data, and manuscript writing; MG: contributed to study concept, data acquisition, and manuscript revision; BFMB: contributed to study concept, study design, data analysis, interpretation of data, manuscript revision, and supervision; PZ: contributed to study design, data analysis, interpretation of data, manuscript writing, manuscript editing, and supervision.

Corresponding author

Correspondence to Jan Krhut.

Ethics declarations

Conflict of interest

Michal Rejchrt is an investigator for STIMVIA; Jan Krhut is a consultant and investigator for STIMVIA; Marcel Gärtner an investigator for STIMVIA; Bertil Blok is a member of the Scientific Advisory Board at STIMVIA; Peter Zvara has no conflicts of interest to declare.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Research involving human participants and/or animals

The study was conducted in accordance with the principles of the Declaration of Helsinki, World Medical Association. An independent institutional ethics committee of Příbram Regional Hospital approved this study protocol, data collection plan, and ICF (Nr.PB205/21). The primary trials were registered under ClinicalTrial.gov nr. 05211193 and EudraCT nr. 2019-003321-14.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rejchrt, M., Krhut, J., Gärtner, M. et al. Effect duration of the initial course of peroneal electrical Transcutaneous NeuroModulation in patients with overactive bladder. World J Urol 41, 1629–1634 (2023). https://doi.org/10.1007/s00345-023-04394-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-023-04394-z

Keywords

Search

Navigation